Methylation of the RASSF1A and RARβ genes as a candidate biomarker for lung cancer

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 1067-1071

  Li, Wen ^a   Deng, Jing ^a   Jiang, Pei ^a   Zeng, Xiaoxi ^a   Hu, Shunqin ^a   Tang, Jianxin ^a  

^a HUNAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Lung cancer; Methylation; Methylation specific polymerase chain reaction; RAR gene; Ras association domain family 1 A gene

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; DNA METHYLATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION;

EID: 84859465611     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.517     Document Type: Article

References (27)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer Statistics. CA Cancer J Clin 56: 106-130, 2006.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Jin YT, Xu YC, Yang RD, Huang CF, Xu CW and He XZ: Familial aggregation of lung cancer in a high incidence area in China. Br J Cancer 92: 1321-1325, 2005.
4. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
5. Jemal A, Tiwael RC, Murray T, et al: Cancer statistics. CA Cancer J Clin 54: 92-119, 2004.
6. Hirsch FR, Merrick DT and Franklin WA: Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J 19: 1151-1158, 2002.
7. Anglim PP, Alonzo TA and Laird-Offringa IA: DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 23: 81, 2008.
8. Nephew KP: What will it take to obtain DNA methylation markers for early cervical cancer detection. Gynecol Oncol 112: 291-292, 2009.
9. Zhang Y, Wang R, Song H, Huang G, Yi J, Zheng Y, Wang J and Chen L: Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 303: 21-28, 2011.
10. Choi JE, Kim DS, Kim EJ, Chae MH, Cha SI, Kim CH, Jheon S, Jung TH and Park JY: Aberrant methylation of ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet 187: 80-84, 2008.
11. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K and Gao B: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699, 2001.
12. Honorio S, Agathanggelou A, Schuermann M, Pankow W, Viacava P and Maher ER: Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene22: 147-150, 2003.
13. Grote HJ, Schmiemann V, Geddert H, Bocking A, Kappes R and Gabbert HE: Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 108: 129-134, 2006.
14. Wang Y, Yu Z, Wang T, Zhang J, Hong L and Chen L: Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 56: 289-294, 2007.
15. Maruyama R, Toyooka S, Toyooka KO, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 8: 514-519, 2002.
16. Neyaz MK, Kumar RS, Hussain S, et al: Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers13: 597-606, 2008.
17. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): 4-11, 2005.
18. Hesson LB, Cooper WN and Latif F: The role of RASSF1A methylation in cancer. Dis Markers 23: 73-87, 2007.
19. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C and Lahm H: Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer54: 109-116, 2006.
20. Toyooka S, Suzuki M, Maruyama R, Toyooka KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T, Shimizu N and Gazdar AF: The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 91: 771-774, 2004.
21. Toyooka S, Suzuki M, Tsuda T, Toyooka KO, Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N, Minna JD and Gazdar AF: Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110: 462-464, 2004.
22. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103: 153-160, 2003.
23. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK and Risk JM: Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 94: 561-568, 2006.
24. Chan EC, Lam SY, Tsang KW, Lam B, Ho JC, Fu KH, Lam WK and Kwong YL: Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res 8: 3741-3746, 2002.
25. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H and Tanimoto M: Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 11: 1219-1225, 2005.
26. Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD and Gazdar AF: Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92: 1303-1307, 2000.
27. Zöchbauer-Müller S, Minna JD and Gazdar AF: Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7: 451-457, 2002.